Identification and evaluation of fragmentation pathways of PDE-5 inhibitor analogues using LC-QTOF-MS

LC-QTOF-MS를 이용한 발기부전치료제 유사물질의 fragmentation pathway 분석

  • Received : 2015.06.22
  • Accepted : 2015.07.15
  • Published : 2015.08.25


Phosphodiesterase type 5 inhibitors (PDE-5 inhibitors) are used in the treatment of erectile dysfunction. In recent years, a number of reports have been conducted on dietary supplements contaminated with PDE-5 analogues. In this study, 58 analogues of PDE-5 inhibitors were sorted into five groups: tadalafil, sildenafil, hongdenafil, vardenafil, and other analogues. These analogues were then evaluated using a liquid chromatography-quadrupole-time of flight mass spectrometry (LC-QTOF-MS) electrospray ionization mass method. Each compound has a unique fragmentation ion, which can be easily analyzed qualitatively. The fragmentation pathways of the analogues were elucidated based on the QTOF-MS and MS/MS data. Common ions were confirmed for each group by analyzing the structural characteristics and fragmentation pathways. Specifically, common ions were observed at m/z 169.08 and 135.04 (tadalafil analogues), m/z 311.15 and 283.12 (sildenafil analogues and hongdenafil analogues), and m/z 312.16 and 151.09 (vardenafil analogues). The advantage of this method is that the structure of unknown components can be determined by interpreting the product ions. Hence, the developed method can be used for the identification of unknown compounds. Fragmentation pathways may also aid in the detection and identification of PDE-5 inhibitor analogues.


PDE-5;LC-QTOF-MS;fragmentation pathway;identification;unknown compounds


  1. J. H. Lee, H. J. Kim, E. Noh, J. Y. Kim, S. H. Cho, J.-A Do, C.-Y. Yoon, S. Cho and W. S. Kim, J. Pharm. Biomed. Anal., 103, 80-84 (2015).
  2. P. Y. Sacre, E. Deconinck, P. Chiap, J. Crommen, F. Mansion, E. Rozet, P. Courselle and J. O. De Beer, J. Chromatogr., 1218(37), 6439-6447 (2011).
  3. C. N. Man, N. M. Noor and R. Lajis, J. Chromatogr., 1218(39), 7055-7060 (2011).
  4. P. Nikolaou, I. Papoutsis, S. Athanaselis, G. Alevisopoulos, A. Khraiwesh, C. Pistos and C. Spiliopoulou, J. Pharm. Biomed. Anal., 56(3), 577-581 (2011).
  5. R. Patterson, P. Mabe, E. N. Mitchell and W. Cory, Forensic Sci. Int., 222(1-3), 83-88 (2012).
  6. C. S. Ng, T. Y. Law, Y. K. Cheung, P. C. Ng and K. K. Choi, Anal. Methods., 2, 890-896 (2010).
  7. Y. Ren, C. S. Wu and J. L. Zhang, J. Sep. Sci., 35(21), 2847-2857 (2012).
  8. M. E. Hadwiger, M. L. Trehy, W. Ye, T. Moore, J. Allgire and B. Westenberger, J. Chromatogr. A., 1217(48), 7547-7555 (2010).
  9. C. L. Cheng, G. J. Kang and C. H. Chou, J. Chromatogr., 1154(1-2), 222-229 (2007).
  10. M. Park and S. Ahn, J. Forensic Sci., 57(6), 1637-1640 (2012).
  11. Y. Cai, T. G. Cai, Y. Shi, X. L. Cheng, L. Y. Ma, S. C. Ma, R. C. Lin and W. Feng, J. Liq. Chromatogr. Rel. Technol., 33, 1287-1306 (2010).
  12. A. Lanzarotta, J. B. Crowe, M. Witkowski and B. M. Gamble, J. Pharm. Biomed. Anal., 67-68, 22-27 (2012).
  13. F. W. McLafferty. Interpretation of Mass Spectra, third edition. University Science Books, p 51-215, Mill Valley, California, 1980.
  14. A. W. Shindel. Update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J. Sex. Med., 6, 2352-2364 (2009).
  15. C. G. Stief, S. Uckert, A. J. Becker, M. C. Truss and U. Jonas, J. Urol., 159(4), 1390-1393 (1998).
  16. B. J. Venhuis and D. Kaste, J. Pharm. Biomed. Anal., 69, 196-208 (2012).
  17. M. Y. Low, Y. Zeng, L. Li, X. W. Ge, R. Lee and B. C. Bloodworth, H. L. Koh, Drug Saf., 32(12), 1141-1146 (2009).
  18. Illicit erectile dysfunction products in the Netherlands, Assessed 8 Sept 2011.
  19. M. Sugita and M. Miyakawa, Health Preventive Med., 15(4), 244-251 (2010).
  20. S. Singh, B. Prasad, A. A. Savaliya, R. P. Shah and V. M. Gohil, A. Kaur, Trends Anal. Chem., 28(1), 13-28 (2009).
  21. J. B. Guo, Y. Xu, Z. B. Huang, Q. H. He, S. W. Liu, Anal. Chim., 658(2), 197-203 (2010).
  22. S. M. Khalil, Microchim., 158, 233-238 (2007).
  23. C. M. Gryniewicz, J. C. Reepmeyer, J. F. Kauffman and L. F. Buhse, J. Pharm. Biomed. Anal., 49(3), 601-606 (2009).
  24. D. J. Mans, R. J. Callahan, J. D. Dunn and C. M. Gryniewicz-Ruzicka, J. Pharm. Biomed. Anal., 75(5), 153-157 (2013).
  25. D. Z. Mao, X. X. Weng and Y. J. Yang, J. Raman Spectrosc., 43(12), 1985-1990 (2012).
  26. B. J. Venhuis, G. Zomer, M. Hamzink, H. D. Meiring, Y. Aubin and D. de Kaste, J. Pharm. Biomed. Anal., 54(4), 735-741 (2011).
  27. L. Blok-Tip, B. Zomer, F. Bakker, K. D. Hartog, M. Hamzink, J. Ten Hove, M. Vredenbregt, D. de Kaste, Food Addit. Contam., 21(8), 737-748 (2004).
  28. Q. Liang, J. Qu, G. Luo and Y. Wang, J. Pharm. Biomed. Anal., 40(2), 305-311 (2006).
  29. S. R. Gratz, C. L. Flurer and K. A. Wolnik, J. Pharm. Biomed. Anal., 36(3), 525-533 (2004).
  30. M. H. Shin, M. K. Hong, W. S. Kim, Y. J. Lee and Y. C. Jeoung, Food Addit. Contam., 20(9), 793-798 (2003).
  31. R. Yuan and Y. Lin, Pharmacol. Ther., 86(2), 191-198 (2000).
  32. FDA approves Stendra for erectile dysfunction,, Assessed 13 Jan 2001.
  33. O. Shaeer. The Global Online Sexuality Survey (GOSS): The United States of America in 2011 Chapter II: phosphodiesterase inhibitors utilization among English speakers. J. Sex. Med., 10(2), 532-540 (2012).